Insurance holding company Globe Life (NYSE: GL) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 6.7% year on year to $1.6 billion. Its GAAP profit of $3.65 per share was in line with analysts’ consensus estimates.
Is now the time to buy Globe Life? Find out by accessing our full research report, it’s free.
Globe Life (GL) Q2 CY2026 Highlights:
- Net Premiums Earned: $1.30 billion vs analyst estimates of $1.30 billion (6.6% year-on-year growth, in line)
- Revenue: $1.6 billion vs analyst estimates of $1.59 billion (6.7% year-on-year growth, in line)
- Pre-tax Profit: $354.9 million (22.2% margin)
- EPS (GAAP): $3.65 vs analyst expectations of $3.64 (in line)
- Book Value per Share: $78.18 (Consensus is Book Value per Share excl AOCI, so not comparable to our figure)
- Market Capitalization: $14.31 billion
Company Overview
With roots dating back to 1900 and a rebranding from Torchmark Corporation in 2019, Globe Life (NYSE: GL) is an insurance holding company that offers life insurance, supplemental health insurance, and annuity products through various distribution channels.
Revenue Growth
In general, insurance companies earn revenue from three primary sources. The first is the core insurance business itself, often called underwriting and represented in the income statement as premiums earned. The second source is investment income from investing the “float” (premiums collected upfront not yet paid out as claims) in assets such as fixed-income assets and equities. The third is fees from various sources such as policy administration, annuities, or other value-added services. Unfortunately, Globe Life’s 4.8% annualized revenue growth over the last five years was tepid. This fell short of our benchmark for the insurance sector and is a tough starting point for our analysis.
Long-term growth is the most important, but within financials, a half-decade historical view may miss recent interest rate changes and market returns. Globe Life’s annualized revenue growth of 4.6% over the last two years aligns with its five-year trend, suggesting its demand was consistently weak. 
This quarter, Globe Life grew its revenue by 6.7% year on year, and its $1.6 billion of revenue was in line with Wall Street’s estimates.
Net premiums earned made up 81% of the company’s total revenue during the last five years, meaning Globe Life barely relies on non-insurance activities to drive its overall growth.
Net premiums earned command greater market attention due to their reliability and consistency, whereas investment and fee income are often seen as more volatile revenue streams that fluctuate with market conditions.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
Book Value Per Share (BVPS)
Insurers are balance sheet businesses, collecting premiums upfront and paying out claims over time. Premiums collected but not yet paid out, often referred to as the float, are invested and create an asset base supported by a liability structure. Book value per share (BVPS) captures this dynamic by measuring these assets (investment portfolio, cash, reinsurance recoverables) less liabilities (claim reserves, debt, future policy benefits). BVPS is essentially the residual value for shareholders.
We therefore consider BVPS very important to track for insurers and a metric that sheds light on business quality. While other (and more commonly known) per-share metrics like EPS can sometimes be lumpy due to reserve releases or one-time items and can be managed or skewed while still following accounting rules, BVPS reflects long-term capital growth and is harder to manipulate.
Globe Life’s BVPS declined at a 1.5% annual clip over the last five years. However, BVPS growth has accelerated recently, growing by 16% annually over the last two years from $58.06 to $78.18 per share.
Over the next 12 months, Consensus estimates call for Globe Life’s BVPS to grow by 45.9% to $101.85, elite growth rate.
Key Takeaways from Globe Life’s Q2 Results
It was good to see Globe Life meet analysts’ revenue and EPS expectations this quarter. Overall, this quarter was without many surprises. The stock remained flat at $183.74 immediately following the results.
Globe Life underperformed this quarter, but does that create an opportunity to invest right now? We think that the latest quarter is only one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).
